2nd Antibody Engineering Summit 2012
As the 12th FYP for biomedical industry was launched, China's antibody drugs development has ushered in a golden era. According to prediction of askci.com, by 2015, China's antibody drugs industry will record a production value of over 40 billion RMB, among which the sales volume of monoclonal antibody drugs will exceed 18 billion BMB.
In line with policy promotions, R&D technology of new antibody drugs and biosimilars is constantly improving, with cancer, immune diseases and therapeutic antibodies as the main targets. Meantime, humanized antibody, monoclonal antibody and cancer targets also gained much progress. In addition, enterprises have put long-term focus on improving expression of recombinant antibodies by broadening effector and elevating antibody manufacturing scale in antibody production...>>more
The medical conference team at CBI has long been committed to tracking the development and trend of medical industry, by adhering to the CBI principle of conducting in-depth study into the industry and keeping in close contact with industry players. The team takes a third-party perspective and regularly organizes summits on industrial hot issues. The ultimate goal is to serve professionals in the medical community by enhancing mutual understanding among domestic and overseas players, and by facilitating communication among research institutes, manufacturing enterprises and government institutions.
For registration please contact Jessica Quan at
+86 21 5155 0869 or email@example.com
|Add The Calendar|
|Tell a Colleague|
|Antibody Engineering Summit 2012|
To promote development by keeping a domestic foothold and taking a global perspective
To achieve breakthroughs by product upgrading and R&D innovation
To catch main points by specific data analysis and in-depth idea sharing
Panel Discussion & Round Table
To inspire your thoughts by brainstorming and Q&A interaction